Robert D. Siegel
George Washington University, George Washington University Hospital
Papers
2
Total Citations
22
H-Index
2
About
Robert D. Siegel is a leading head and neck surgical oncologist whose research focuses on de-escalating treatment for human papillomavirus–related oropharyngeal squamous cell carcinoma (HPV+ OPSCC). His major contributions center on combining neoadjuvant chemotherapy with transoral robotic surgery (NAC+S) to reduce distant metastasis while minimizing long-term toxicity. In a landmark 2024 study (10 citations), Siegel demonstrated that this approach effectively addresses the leading cause of death in HPV+ OPSCC—distant spread—while preserving quality of life. His 2021 work (12 citations) provided critical two-year follow-up data showing that swallowing function remains stable after NAC+S, offering compelling evidence that patients can avoid the severe dysphagia associated with traditional chemoradiation. Siegel’s research is reshaping treatment paradigms by proving that surgical de-escalation is both oncologically safe and functionally superior. His work has immediate clinical impact, guiding multidisciplinary teams toward less toxic yet equally effective protocols. For students and researchers, Siegel exemplifies how thoughtful trial design can challenge dogma, improve survivorship, and redefine standards of care in HPV-related oropharyngeal cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2